// App-Quantinova.ai

: Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).

Researchers

Presenter

  • Zishuo Hu

Principal Investigators

  • Amir Mortazavi

  • Sumanta K. Pal

  • Primo Lara

  • Tina M. Mayer

  • Seth M Steinberg

  • Christian Mayfield

  • Katherine Graap

  • Marissa Mallek

  • Rene Costello

  • Carlos Diaz

  • Joseph Schonhoft

  • Yipeng Wang

  • Ryan Dittamore

  • Lincy Chu

  • Jane B Trepel

  • Donald P. Bottaro

  • Andrea B. Apolo

Medical Centers

  • National Institute of Health, Bethesda, MD

  • Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH

  • City of Hope, Duarte, CA

  • University of California, San Francisco, CA

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • National Cancer Institute, Rockville, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • National Cancer Institute, Bethesda, MD

  • Epic Sciences, Inc., San Diego, CA

  • Epic Sciences, Inc., San Diego, CA

  • Center for Cancer Research, NCI, NIH, Bethesda, MD

  • Center for Cancer Research, Division of Cancer Treatment and Diagnosis, Bethesda, MD

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

  • Programmed death-ligand 1

Drug/Treatment

  • Cabozantinib

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved